SCHEMBL6092695

SCHEMBL6092695

O=C(CC(c1ccccc1)c1ccccc1)Nc1ccc2ncn(-c3nccs3)c2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.44
LMNA P02545 3/20 0.44
MAPT P10636 3/20 0.44
ALDH1A1 P00352 2/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2D6 P10635 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
HPGD P15428 2/20 0.43
TACR1 P25103 1/20 0.40
NOTUM Q6P988 2/20 0.40
ROCK2 O75116 1/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
NPSR1 Q6W5P4 2/20 0.39
CRHBP P24387 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6092359 0.91 ALDH1A1 (0.46) PDE10ALMNAMAPTALDH1A1NPC1
SCHEMBL4372131 0.82 ALDH1A1 (0.47) PDE10ALMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL6090866 0.77 AR (0.49) PDE10ALMNAMAPTNPC1RAB9A
SCHEMBL6092966 0.77 SMN1; SMN2 (0.45) LMNAMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL4367689 0.76 HPGD (0.49) LMNAMAPTALDH1A1NPC1RAB9A
SCHEMBL6091957 0.74 LMNA (0.54) LMNAMAPTALDH1A1NPC1RAB9A
SCHEMBL6094816 0.74 LMNA (0.54) LMNAMAPTALDH1A1NPC1RAB9A
SCHEMBL4377654 0.72 ANO1 (0.48) PDE10AHTT
SCHEMBL6092686 0.71 MAPT (0.51) LMNAMAPTALDH1A1NPC1RAB9A
SCHEMBL4365495 0.70 NPC1 (0.45) LMNAMAPTALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060036098-A1 Carbonylamino-benzimidazole derivatives as androgen receptor modulators MERCK SHARP & DOHME CORP. 2006-02-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060036098-A1 Carbonylamino-benzimidazole derivatives as androgen receptor modulators AR, SHBG, BRCA1 PDE10A 2439/4885LMNA 2221/4885MAPT 2814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.